$GNW

RESTREPO ROBERT P JR sold $456K of GNW

RESTREPO ROBERT P JR sold 50,000 shares of GENWORTH FINANCIAL INC (GNW) at $9.12 ($0.46M total) on 2026-05-22.

Original reporting
SEC EDGAR · RESTREPO ROBERT P JR
Published May 26, 2026, 8:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 26, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GNW
Neutral
medium confidence
Mentioned
$GNW
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GNWNeutralMed
01

Why it matters

This is a disclosure of insider activity without any stated linkage to company performance, guidance, or corporate actions; trading impact is therefore likely sentiment-driven and short-lived.

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone is unlikely to drive a durable repricing.

03

What to watch

The article provides no context on total holdings over time, whether other insiders sold/bought, or whether the director’s remaining stake is materially different.

Relevance 8/10Timing: Immediate (today’s SEC Form 4 filing may affect intraday sentiment/flow).

Background

The article is an SEC Form 4 insider transaction: director Robert P. Restrepo sold Genworth Financial shares on 2026-05-22; the filing was made 2026-05-26.

Company-level read

Ticker impact

$GNWNeutralMedium confidence
Context

Genworth Financial director Robert P. Restrepo sold 50,000 shares in an open-market transaction at $9.1211/share, per SEC Form 4.

Expected impact

Likely limited near-term impact; any move is more about sentiment/positioning than new company information.

Evidence & confidence

The filing is an ownership-change disclosure with no accompanying operational or financial news; also the sale is not stated as part of a 10b5-1 plan, which can increase noise but still lacks fundamentals.

Market effects

Minimal; single-insider sale does not typically reset sector expectations for financials/insurers.

None indicated; disclosure is company-specific.

None indicated; no cross-border deal/regulatory action mentioned.

Counterpoint

Director sales can be routine liquidity events (taxes, diversification) and may not reflect bearish expectations.

Key entities

  • Genworth Financial Inc

    Subject of the insider transaction disclosure (director sale of 50,000 shares).

  • RESTREPO ROBERT P JR

    Director who executed the open-market sale; holdings after transaction reported as 92,655 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GNWMed

Genworth (GNW) Added $500M to its Repurchase Authorization. Can Enact (ACT) Capital Returns Fund the Buybacks?

Genworth Financial (GNW) increased its share buyback authorization by $500M, bringing total unused capacity to $588M. The move relies on capital returns from its majority-owned subsidiary, Enact Holdings (ACT), which has raised its expected 2026 capital returns to $550M-$600M. GNW has already repurchased 30M shares for $262M under the prior authorization. However, the company faces risks, including dependence on ACT's performance and legacy insurance challenges.

$GNWMed

Genworth leans on mortgage unit, CareScout to offset Q2 LTC liabilities

Genworth Financial reported Q2 net income of $47 million and said it is relying on mortgage insurance Enact and its CareScout aging-care platform to offset long-term care insurance liabilities. CareScout had 1,450 matches in Q2 and expects about $25 million in 2026 CareScout Services revenue. Enact guidance implies $445M to $485M capital returns in 2026. Genworth’s AXA appeal decision is expected in 3 to 6 months.

$GNWMed

Genworth Financial Q2 Earnings Call Highlights

Genworth Financial (NYSE:GNW) discussed Q2 results and capital allocation tied to Enact. Enact’s PMIER sufficiency was 161% (about $1.9B above requirements) and returned $103M of capital to Genworth. GNW raised 2025 capital-return outlook to $445M-$485M and increased 2026 buybacks to $225M-$250M. CareScout network and worksite insurance approvals expanded; closed block loss was $110M adjusted.

$GNWMed

GENWORTH FINANCIAL INC (GNW): Results of Operations and Financial Condition

GENWORTH FINANCIAL INC (GNW) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Genworth Financial Announces Second Quarter 2026 Results Strategic Highlights • Strong capital returns from Enact, with $103M received in the quarter • Repurchased $62M of shares in the quarter; $918M since program inception through June 30, 2026 • CareScout delivere